These data suggest that the BR2 peptide containing PR-PPD can enhance the growth inhibitor effect of Gefitinib, suggesting that combination treatment of BR2-2xPR-PPD peptides with Gefitinib may serve as a new perspective in NSCLC treatment. Here, PGR is linked to non-small cell lung carcinoma.